Abbott said the increase in diagnostics revenue was driven by adoption of the company's Alinity family of diagnostic instruments.
The company reported performance changes that led to the product recall and said it is pursuing eventual FDA clearance for the devices.
Abbott highlighted its next-generation Alinity platforms, and Caris discussed its plans to provide precision oncology services.
News items from the in vitro diagnostics industry for the week of Dec. 16, 2019.
The company's newest products and planned updates reveal a focus on operational efficiency and increasing automation for core lab management.
The company said it plans to move all its immunoassays to a single vendor, representing an opportunity worth between $250 million and $400 million annually.
The Australian Red Cross Blood Service will use the Alinity s System to process its blood tests and improve lab automation.
Within Diagnostics, year-over-year core laboratory Q3 revenues rose 8 percent to $1.18 billion but molecular diagnostics revenues fell 8 percent to $111 million.
The FDA gave the nod to Shenzhen Bioeasy Biotechnology for two lateral flow immunoassays that provide preliminary results in detecting marijuana in urine.
The test can be used to help doctors in the emergency room diagnose heart attacks faster and more accurately than other troponin tests on the market, Abbott said.